Cancer Therapy News and Research

RSS

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

Recent recommendations by the US Preventive Task Force on Breast Cancer advising that women under the age of 50 should not get routine mammograms have resulted in fierce debate within the medical community. According to a new oncology study from ORC, an Infogroup Company, 70 percent of oncologists and 60 percent of ob-gyns disagree with the assertion that women should not get mammograms before the age of 50.

20 May 2010

Curis announces inclusion in NASDAQ Biotechnology Index

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.

19 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Sonablate HIFU treatment now available in Bermuda for patients with prostate cancer

US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies, is pleased to announce that its HIFU treatment for prostate cancer is now available in Bermuda. King Edward VII Memorial Hospital in Bermuda joins more than 100 centers in 30-plus countries to offer the innovative treatment with the Sonablate 500 medical device.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, successfully launched its products in the USA. EvoLife Laboratories is present at the annual Oncology Nursing Society Congress 2010 in San Diego and utilizes this opportunity to further engage with nurses and caregivers.

15 May 2010

US Oncology Specialty passes VAWD accreditation program

US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.

15 May 2010

Still River Systems announces clinical beam extraction from world's smallest high-energy proton therapy accelerator

Still River Systems, Inc. announces successful clinical beam extraction from the first production unit of the world's smallest high-energy proton therapy accelerator. Powerful proton beams are used for the precise treatment of cancer by delivering a highly focused beam of radiation to the tumor while reducing the damage to surrounding healthy tissue and vital organs.

15 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Johns Hopkins Children's Center neonatologist Christoph Lehmann, M.D., has joined the nation's leading watchdog organization on health-care quality, the National Quality Forum (NQF), as a member of its newly formed Health Information Technology (HIT) advisory committee.

14 May 2010

Increase in use of imaging scans underscores need for evidence-based protocols in cancer care

New research showing a more than 30 percent annual increase in the use of high-tech imaging scans in older cancer patients underscores the need for evidence-based protocols in cancer care, said MedSolutions, a leading provider of medical management services.

14 May 2010

CIGNA adds CTCA to national network

Recognizing the importance of access, quality and choice for its many customers who have been touched by cancer, CIGNA has entered into a new agreement that opens the doors to comprehensive, integrative care at Cancer Treatment Centers of America (CTCA).

14 May 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

13 May 2010

Research investigates MDR in human HCC

Hepatocellular carcinoma responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Cancer Therapy News and Research

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

Curis announces inclusion in NASDAQ Biotechnology Index

New DVS radiation measurement device for prostate cancer treatment

Sonablate HIFU treatment now available in Bermuda for patients with prostate cancer

152 research and training grants awarded to researchers at 93 institutions nationwide

EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers

US Oncology Specialty passes VAWD accreditation program

Still River Systems announces clinical beam extraction from world's smallest high-energy proton therapy accelerator

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Increase in use of imaging scans underscores need for evidence-based protocols in cancer care

CIGNA adds CTCA to national network

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Research investigates MDR in human HCC

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Researchers develop new technology to manage prostate cancer treatment

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Genetic tests represent future of cancer care for women

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

New computer-based tool developed to benefit cancer patients

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News